Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient-Centered Approach to Surgical Prevention of Ovarian Cancer: A Nonrandomized Clinical Trial.

JAMA network open·2026

Same author

Correction: PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma.

Cancer research communications·2025

Same author

Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.

Cell·2025

Same author

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Nature communications·2025

Same author

Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.

Cancer research communications·2025

Same author

SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer.

Cancer research·2025

Search research articles

Related Experiment Video

Updated: May 22, 2025

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

A Rapid and Reliable Test for BRCA1 Promoter Hypermethylation in Paraffin Tissue Using Pyrosequencing.

Ruben Bacares¹, Robert Soslow^1,2, Narciso Olvera^3,4

¹Departments of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Diagnostics (Basel, Switzerland)

|March 13, 2025

Summary

A new pyrosequencing assay effectively measures BRCA1 promoter methylation in ovarian cancer. This validated method accurately predicts response to PARP inhibitors, offering a dynamic biomarker for treatment selection.

Keywords:

BRCA hypermethylation pyrosequencing

More Related Videos

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Published on: January 30, 2017

Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

Published on: April 30, 2019

Related Experiment Videos

Last Updated: May 22, 2025

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Field Postmortem Rabies Rapid Immunochromatographic Diagnostic Test for Resource-Limited Settings with Further Molecular Applications

Published on: June 29, 2020

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Published on: January 30, 2017

Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test

Published on: April 30, 2019

Area of Science:

Oncology
Molecular Biology
Biomarker Development

Background:

Ovarian cancers with BRCA1/BRCA2 mutations are sensitive to PARP inhibitors.
BRCA1 promoter methylation is a dynamic biomarker for predicting PARP inhibitor response.
Methylation status may be a more precise indicator of homologous recombination deficiency than genomic scars.

Purpose of the Study:

To validate a pyrosequencing assay for assessing BRCA1 promoter methylation.
To establish the reliability and accuracy of the assay for clinical use.

Main Methods:

Tumor DNA from high-grade serous ovarian carcinoma was analyzed for methylation at 11 CpG sites near the BRCA1 transcription start site.
A dilution series experiment was conducted to determine assay sensitivity.
Assay reproducibility was confirmed through triplicate runs.

Main Results:

The pyrosequencing assay showed a high correlation (R² = 0.9945) between predicted and observed methylation levels.
The assay demonstrated 100% concordance across all tested ovarian cancer cases with a 10% methylation cutoff.
Excellent intra- and inter-run reproducibility was achieved.

Conclusions:

The validated PyroMark Q24 pyrosequencing assay is a reliable method for detecting BRCA1 promoter methylation in ovarian cancer.
This assay is approved for clinical use and can serve as a valuable biomarker for PARP inhibitor therapy.
The assay provides a dynamic and precise assessment of homologous recombination deficiency.